therapeutic effects of cannabidiol on methamphetamine abuse: a review of preclinical study

As a strong and addictive psychostimulant, methamphetamine (meth) is often misused worldwide. although relapse is the greatest challenge to the effective treatment of drug dependency, now, for meth addiction, there is not available accepted pharmacotherapy. to characterize a probable new target in this indication, a biological system comprised of endocannabinoids, known as the endocannabinoid system (ecs), has been advised. as a nonpsychotomimetic phytocannabinoid in cannabis sativa, cannabidiol (cbd) has been used in preclinical and clinical studies for treating neuropsychiatric disorders. in this review article, we focus on the effects of cbd in the treatment of addiction in a preclinical investigation concerning the pharmaceutic effectiveness and the underlying mechanisms of action on drug abuse specially meth. growing evidence shows that cbd is a potential therapeutic agent in reducing drug reward, as evaluated in conditioned place preference (cpp), brain-stimulation reward paradigms, and self- administration. furthermore, cbd plays an effective role in decreasing relapse in animal research. through multiple-mechanisms, there is a belief that cbd modulates brain dopamine responding to meth, resulting in a reduction of meth-seeking behaviors. as our studies indicate, cbd can decrease meth addiction-associated problems, for example, symptoms of withdrawal and craving. it is needed for conducting more preclinical investigations and upcoming clinical trials to entirely assess the cbd capability as interference for meth addiction.